Skip to search formSkip to main contentSkip to account menu

Eprex

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
BACKGROUND Recombinant human erythropoietin is the cornerstone of therapy for anemia associated with chronic kidney disease or… 
2009
2009
INTRODUCTION PDpoietin is a recombinant erythropoietin alfa that has been introduced by a manufacturer in Iran. We assessed the… 
2007
2007
Concomitant HIV and hepatitis C virus (HCV) is a common yet complex coinfection. The present document is a practical guide for… 
2007
2007
Aim:  Treatment of renal anaemia with epoetin is well established. However, epoetin is expensive. Biogeneric epoetin with proven… 
2005
2005
BackgroundRecombinant human erythropoietin (EPO) is used for the treatment of last stage renal anemia. A new EPO preparation was… 
2003
2003
OBJECTIVE Patients with renal failure and undergoing hemo- (HD) or peritoneal dialysis are under oxidative stress which is… 
1994
1994
In this study, a cohort of 109 patients with multiple myeloma were followed prospectively. Eight patients (7%) were found to have… 
1994
1994
Intravenous recombinant human erythropoietin (Eprex Cilag) was used in 28 hemodialyzed children, treated in 3 French paediatric…